Tavneos Capsule
NDC Package 73556-168-96

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Tavneos (avacopan) capsules is tAVNEOS is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. This formulation utilizes a capsule delivery system. Marketed by Chemocentryx, Inc., this product is identified by NDC 73556-168 and is authorized under FDA application NDA214487.

Identification & Billing

NDC Package Code
73556-168-96
Package Description
1 BOTTLE, PLASTIC in 1 CARTON / 30 CAPSULE in 1 BOTTLE, PLASTIC
Product Code
73556-168
11-Digit Billing Format
73556016896
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Tavneos
Non-Proprietary Name
Avacopan
Substance Name
Avacopan
Dosage Form
Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
AVACOPAN 10 mg/1
Pharmacologic Class
Usage Information
TAVNEOS is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use.

Regulatory & Marketing

Labeler Name
Chemocentryx, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA214487
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
10-18-2021
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
Yes

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (73556-168). Click a package code to view its specific billing and regulatory data.

73556-168-01
1 BOTTLE, PLASTIC in 1 CARTON / 180 CAPSULE in 1 BOTTLE, PLASTIC
73556-168-02
1 BOTTLE, PLASTIC in 1 CARTON / 30 CAPSULE in 1 BOTTLE, PLASTIC

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 73556-168-96 identifies a specific commercial package of 1 bottle, plastic in 1 carton / 30 capsule in 1 bottle, plastic of Tavneos, a human prescription drug labeled by Chemocentryx, Inc.. This capsule is formulated for oral use and contains avacopan as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Chemocentryx, Inc. on October 18, 2021. The current certification is valid through December 31, 2027.

How is this Chemocentryx, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 73556016896. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
73556-168-96
11-Digit CMS (5-4-2)
73556-0168-96

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.